Observational Study of Mecapegfilgrastim Injection to Prevent Neutropenia After Tumor Treatment

What this Trial Is About

Researchers are conducting a multicenter observational real-world study to observe and evaluate the use of Mecapegfilgrastim Injection in patients with solid malignant tumors. The study focuses on assessing the efficacy and safety of this injection to prevent neutropenia in tumor patients undergoing radiotherapy, chemotherapy, or immunotherapy. Participants are those who require such treatments and are considered by researchers to need Mecapegfilgrastim for primary or secondary prevention of neutropenia. Participants will receive Mecapegfilgrastim Injection at a fixed dose of 6 mg or 100 gkg 24 hours after the end of each treatment cycle. The study monitors these patients during their routine tumor treatment to collect real-world data on the prevention of neutropenia. There are no placebo or comparator groups since this is an observational study. During the study, researchers will track the incidence of febrile neutropenia FN from enrollment until three weeks after the end of treatment, as well as the incidence of grade 3 and 4 neutropenia up to six weeks after treatment. Participants will be observed for treatment outcomes and safety, with data collected from their regular medical care visits. The total duration of participation varies based on their treatment timelines.

Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection